Aptevo Therapeutics (APVO) Return on Capital Employed (2016 - 2026)
Aptevo Therapeutics (APVO) posted Return on Capital Employed of 141.95% for Q1 2026, down 13.53% sequentially from 125.03% in Q4 2025, and up 22466.0% YoY from N/an in Q1 2025.
Aptevo Therapeutics (APVO) Return on Capital Employed (2016 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Return on Capital Employed for 11 years, with the latest figure at 141.95% in Q1 2026.
- Quarterly Return on Capital Employed rose 22466.0% year-over-year to 141.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 141.95% (up 22466.0% YoY) and the FY2025 annual result came in at 171.5%, up 411.0% from the prior year.
- Return on Capital Employed fell to 141.95% in Q1 2026 per APVO's latest filing, from 125.03% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 62.77% in Q2 2022 and troughed at 366.61% in Q1 2025.
- A 5-year average of 175.65% and a median of 142.46% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 17845 bps in 2025, then surged 22466 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 118.11% in 2022, then slumped by 30 bps to 153.93% in 2023, then plunged by 74 bps to 268.54% in 2024, then jumped by 53 bps to 125.03% in 2025, then dropped by 14 bps to 141.95% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 141.95%, 125.03%, and 170.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | -223.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -223.63% |
| Mar 31, 2026 | -141.95% |
| Dec 31, 2025 | -125.03% |
| Sep 30, 2025 | -170.09% |
| Jun 30, 2025 | -342.65% |
| Mar 31, 2025 | -366.61% |
| Dec 31, 2024 | -268.54% |
| Sep 30, 2024 | -268.85% |
| Jun 30, 2024 | -239.06% |
| Mar 31, 2024 | -188.16% |
| Dec 31, 2023 | -153.93% |
| Sep 30, 2023 | -142.46% |
| Jun 30, 2023 | -125.46% |
| Mar 31, 2023 | -106.91% |
| Dec 31, 2022 | -118.11% |
| Sep 30, 2022 | -91.03% |
| Jun 30, 2022 | -62.77% |
| Mar 31, 2022 | -74.43% |
| Dec 31, 2021 | -83.77% |
| Sep 30, 2021 | -68.38% |